These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8473411)

  • 1. Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
    Hedin L; Olsson B; Diczfalusy M; Flyg C; Petersson AS; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1993 Apr; 76(4):962-7. PubMed ID: 8473411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models.
    Baldwin PA; Klingbeil CK; Grimm CJ; Longenecker JP
    Pharm Res; 1990 May; 7(5):547-52. PubMed ID: 2367323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency.
    Russo L; Moore WV
    J Clin Endocrinol Metab; 1982 Nov; 55(5):1003-6. PubMed ID: 6889608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
    Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
    Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary human growth hormone measurement using a highly sensitive sandwich enzyme immunoassay: diagnostic and therapeutic uses in patients with growth hormone deficiency.
    Kohno H; Murakami Y; Kodaira T
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1496-500. PubMed ID: 2229307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subcutaneous and intranasal administration of ovine corticotropin-releasing hormone in man: comparison with intravenous administration.
    DeBold CR; Sheldon WR; DeCherney GS; Jackson RV; Nicholson WE; Island DP; Orth DN
    J Clin Endocrinol Metab; 1985 May; 60(5):836-40. PubMed ID: 2984233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children.
    Christiansen JS; Orskov H; Binder C; Kastrup KW
    Acta Endocrinol (Copenh); 1983 Jan; 102(1):6-10. PubMed ID: 6681687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of subcutaneous and intramuscular administration of human growth hormone (hGH) and increased growth rate by daily injection of hGH in GH deficient children.
    Takano K; Shizume K; Hibi I
    Endocrinol Jpn; 1988 Jun; 35(3):477-84. PubMed ID: 3197659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients.
    Jørgensen JO; Flyvbjerg A; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
    J Clin Endocrinol Metab; 1988 Jul; 67(1):36-40. PubMed ID: 3288652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.
    Lewis AL; Jordan F; Patel T; Jeffery K; King G; Savage M; Shalet S; Illum L
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4364-71. PubMed ID: 26425883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.
    Evans WS; Vance ML; Kaiser DL; Sellers RP; Borges JL; Downs TR; Frohman LA; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1985 Nov; 61(5):846-50. PubMed ID: 3930551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal absorption of growth hormone in normal subjects: studies with four different formulations.
    Laursen T; Ovesen P; Grandjean B; Jensen S; Jørgensen JO; Illum P; Christiansen JS
    Ann Pharmacother; 1994; 28(7-8):845-8. PubMed ID: 7949497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.
    Weeke J; Christensen SE; Orskov H; Kaal A; Pedersen MM; Illum P; Harris AG
    J Clin Endocrinol Metab; 1992 Jul; 75(1):163-9. PubMed ID: 1619006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of human follicle-stimulating hormone in gonadotropin-deficient men.
    Handelsman DJ; Turner L; Boylan LM; Conway AJ
    J Clin Endocrinol Metab; 1995 May; 80(5):1657-63. PubMed ID: 7745014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) treatment in short normal children: absence of influence of time of injection and resistance to GH autofeedback.
    Chanoine JP; Vanderschueren-Lodeweyckx M; Maes M; Thiry-Counson G; Craen M; Van Vliet G
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1269-75. PubMed ID: 1955508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of acute and chronic growth hormone (GH) administration on GH secretion in patients with idiopathic GH deficiency.
    Hanew K; Goh M; Sato S; Shimizu Y; Sasaki A; Aida M; Yoshinaga K
    J Clin Endocrinol Metab; 1988 Apr; 66(4):715-21. PubMed ID: 3126213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men.
    Hashimoto Y; Kamioka T; Hosaka M; Mabuchi K; Mizuchi A; Shimazaki Y; Tsunoo M; Tanaka T
    J Clin Endocrinol Metab; 2000 Feb; 85(2):601-6. PubMed ID: 10690862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio.
    Lee WA; Narog BA; Patapoff TW; Wang YJ
    J Pharm Sci; 1991 Aug; 80(8):725-9. PubMed ID: 1791529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.
    Lee WA; Ennis RD; Longenecker JP; Bengtsson P
    Pharm Res; 1994 May; 11(5):747-50. PubMed ID: 8058647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.